Atlas Trials

Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Clinical trial NCT04600947 · UNKNOWN

Trial details

NCT number
NCT04600947
Sponsor
Taizhou HoudeAoke Biomedical Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Start date
2020-12-30
Primary completion
2022-05-30
Enrollment
69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.